PDCD1LG2 and neoplasm: This upregulated PD-1 binds to its ligands, PD-L1 or PD-L2, which are abundantly expressed on the surfaces of tumor cells, thereby impairing antigen presentation to T cells and interrupting the antigen presentation phase of the tumor immune process (Figure 1).